IL308868A - Combined treatments with SETD2 inhibitors - Google Patents

Combined treatments with SETD2 inhibitors

Info

Publication number
IL308868A
IL308868A IL308868A IL30886823A IL308868A IL 308868 A IL308868 A IL 308868A IL 308868 A IL308868 A IL 308868A IL 30886823 A IL30886823 A IL 30886823A IL 308868 A IL308868 A IL 308868A
Authority
IL
Israel
Prior art keywords
combination therapies
setd2
inhibitors
setd2 inhibitors
therapies
Prior art date
Application number
IL308868A
Other languages
English (en)
Hebrew (he)
Inventor
Maria Alejandra Raimondi
Jennifer Anne Totman
Vinny Motwani
Katherine Louise Cosmopoulos
Dorothy Brach
Daniel T Dransfield
Original Assignee
Epizyme Inc
Maria Alejandra Raimondi
Jennifer Anne Totman
Vinny Motwani
Katherine Louise Cosmopoulos
Dorothy Brach
Daniel T Dransfield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Maria Alejandra Raimondi, Jennifer Anne Totman, Vinny Motwani, Katherine Louise Cosmopoulos, Dorothy Brach, Daniel T Dransfield filed Critical Epizyme Inc
Publication of IL308868A publication Critical patent/IL308868A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL308868A 2021-06-09 2022-06-08 Combined treatments with SETD2 inhibitors IL308868A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163208882P 2021-06-09 2021-06-09
PCT/US2022/032718 WO2022261243A1 (en) 2021-06-09 2022-06-08 Combination therapies with setd2 inhibitors

Publications (1)

Publication Number Publication Date
IL308868A true IL308868A (en) 2024-01-01

Family

ID=84425539

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308868A IL308868A (en) 2021-06-09 2022-06-08 Combined treatments with SETD2 inhibitors

Country Status (10)

Country Link
US (1) US20240299352A1 (enExample)
EP (1) EP4351552A4 (enExample)
JP (1) JP2024522184A (enExample)
KR (1) KR20240019241A (enExample)
CN (1) CN117794543A (enExample)
AU (1) AU2022288073A1 (enExample)
CA (1) CA3221071A1 (enExample)
IL (1) IL308868A (enExample)
MX (1) MX2023014663A (enExample)
WO (1) WO2022261243A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272379B2 (en) 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
CN121695288A (zh) 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法
WO2025034951A1 (en) * 2023-08-09 2025-02-13 Enanta Pharmaceuticals, Inc. Pharmaceutical compounds and compositions as c-kit kinase inhibitors
TW202532067A (zh) * 2023-12-13 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有吡唑環及雙環雜芳基的化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
WO2015150097A1 (en) * 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
US20170232030A1 (en) * 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
IL272379B2 (en) * 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) * 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
WO2020112872A1 (en) * 2018-11-30 2020-06-04 Epizyme, Inc. Methods of treating whsc1-overexpressing cancers by inhibiting setd2
CN121695288A (zh) * 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法

Also Published As

Publication number Publication date
EP4351552A4 (en) 2025-06-18
KR20240019241A (ko) 2024-02-14
US20240299352A1 (en) 2024-09-12
CN117794543A (zh) 2024-03-29
JP2024522184A (ja) 2024-06-11
MX2023014663A (es) 2024-05-08
CA3221071A1 (en) 2022-12-15
AU2022288073A1 (en) 2023-12-07
WO2022261243A1 (en) 2022-12-15
EP4351552A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
IL310919A (en) Combined treatments
IL291659A (en) Combined treatments
SI3999506T1 (sl) Zaviralci PARP1
ZA202212919B (en) Transposition-based therapies
ZA202102016B (en) Combination therapies
ZA202102015B (en) Combination therapies
SG11202106520VA (en) Kif18a inhibitors
PT3849534T (pt) Combinação de dasatinib e adagrasib para utilização no tratamento de cancro do pulmão de células não pequenas
HUE070338T2 (hu) Kombinációs terápiák
GB202107907D0 (en) Combination therapies
EP3592354A4 (en) COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS
IL308333A (en) Combined treatments
IL287670A (en) Combined treatments including apremilaste and tyk2 inhibitors
IL288306A (en) Combined treatments using cdk inhibitors
EP4351552A4 (en) COMBINATION THERAPIES WITH SETD2 INHIBITORS
IL276013A (en) pi4kiiibeta inhibitors
IL287667A (en) Combined treatments
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL283112A (en) LOX inhibitors
GB201916906D0 (en) Combination therapies
GB202300007D0 (en) Combination therapies
GB201809295D0 (en) Lox inhibitors
EP4199929A4 (en) Combination therapies with olig2 inhibitors
IL274415A (en) Combined treatments with EZH2 inhibitors
HK40112303A (en) Combination therapies with setd2 inhibitors